Ryan D Morin
Overview
Explore the profile of Ryan D Morin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
9082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coyle K, Dreval K, Hodson D, Morin R
Blood Adv
. 2025 Jan;
PMID: 39853274
Comprehensive genetic analysis of tumors with exome or whole genome sequencing has enabled the identification of the genes that are recurrently mutated in cancer. This has stimulated a series of...
2.
Sahasrabuddhe A, Chen X, Ma K, Wu R, Liang H, Kapoor R, et al.
Cancer Discov
. 2025 Jan;
PMID: 39820335
The role of ubiquitin-mediated degradation mechanisms in the pathogenesis of diffuse large B cell (DLBCL) and follicular lymphoma (FL) is not completely understood. We show that conditional deletion of the...
3.
4.
Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, et al.
Br J Haematol
. 2024 Sep;
205(5):2067-2071.
PMID: 39267295
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial...
5.
Collinge B, Ben-Neriah S, Hilton L, Alduaij W, Tucker T, Slack G, et al.
Blood
. 2024 Aug;
144(15):1611-1616.
PMID: 39133931
Fluorescence in situ hybridization (FISH) using break-apart probes is recommended for identifying high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2). Unbalanced MYC break-apart patterns, in which the red or...
6.
Riley R, Negri G, Cheng S, Spencer Miko S, Morin R, Morin G
J Proteome Res
. 2024 Jun;
23(8):3704-3715.
PMID: 38943634
Proteome coverage and accurate protein quantification are both important for evaluating biological systems; however, compromises between quantification, coverage, and mass spectrometry (MS) resources are often necessary. Consequently, experimental parameters that...
7.
Hilton L, Collinge B, Ben-Neriah S, Alduaij W, Shaalan H, Weng A, et al.
Blood
. 2024 May;
144(5):525-540.
PMID: 38701426
Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both...
8.
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment
Benoit A, Abraham M, Li S, Kim J, Estrada-Tejedor R, Bakadlag R, et al.
Int J Hematol
. 2024 Jan;
119(3):275-290.
PMID: 38285120
Diffuse large B-cell lymphoma (DLBCL) relapses in approximately 40% of patients following frontline therapy. We reported that STAT6 mutations are enriched in relapsed/refractory DLBCL (rrDLBCL) samples, suggesting that JAK/STAT signaling...
9.
Hilton L, Scott D, Morin R
Semin Hematol
. 2023 Dec;
60(5):267-276.
PMID: 38151380
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous both in clinical outcomes and the underlying disease biology. Over the last 2 decades, several different approaches for dissecting biological heterogeneity have emerged....
10.
Davies J, Hilton L, Jiang A, Barrans S, Burton C, Johnson P, et al.
Blood Adv
. 2023 Aug;
7(20):6156-6162.
PMID: 37595057
No abstract available.